EUROPE’S ANTIBIOTIC INVESTMENTS STAGNATE AS RESISTANCE CRISIS LOOMS

By Jonathan Smith at Labiotech.eu

Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and societal awareness could spell fresh investments in the coming years.

Over the last decade, pressure has been mounting on healthcare systems as infectious microbes become harder and harder to fight with antibiotics. Some strains of bacteria, including Clostridium difficile, are seen as urgent threats that need a better range of antibiotic treatments.… continue reading>>

More To Explore

Contact Us

Reach US

Linkedin Twitter

A-2-Z - Digital Accessibility and Marketing

 

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.


Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

  

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).